Results 161 to 170 of about 76,900 (255)

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Comparative analysis of the effects of cyclophosphamide and dexamethasone on intestinal immunity and microbiota in delayed hypersensitivity mice. [PDF]

PLoS One
Li X, Wen R, Chen B, Luo X, Li L, Ai J, Yu J.   +6 more
europepmc   +1 more source

European Guidelines on Eosinophilic Esophagitis: Evidence‐Based Statements and Recommendations for Diagnosis and Management in Children and Adults. Part 1: Diagnosis, Epidemiology and Natural History

Allergy, EarlyView.
The European evidence‐based guidelines on eosinophilic esophagitis (Part 1). This infographic summarizes the methodological framework and core clinical outputs of the updated consensus developed by multidisciplinary experts from EUREOS, EAACI, ESPGHAN, and ESP.
Alfredo J. Lucendo, Javier Molina‐Infante, Ángel Arias, Ulrike von Arnim, Henrik Bergquist, Luc Biedermann, Albert J. Bredenoord, Marie Carlson, Javier Chahuan, Jorge Amil Dias, Thomas Eiwegger, Sara Feo‐Ortega, Sandra L. Garcia‐Dionisio, Matteo Ghisa, Jesús González‐Cervera, Thomas Greuter, Danila Guagnozzi, Carolina Gutiérrez‐Junquera, Lucía Gutiérrez‐Ramírez, Cord Langner, Helen Larsson, Anne Lund Krarup, Salvatore Oliva, Alexandra Papadopoulou, Francesca Racca, Cecilio Santander, Edoardo Vincenzo Savarino, Christoph Schlag, Alain M. Schoepfer, Martin A. Storr, Antonio Tejera‐Muñoz, Noam Zevit, Stephen E. Attwood, Alex Straumann   +33 more
wiley   +1 more source

Delayed hypersensitivity reaction to orodispersible budesonide in a case with eosinophilic esophagitis. [PDF]

BMC Gastroenterol, 2020
Andrist CM, Jörg L, Greuter T, Gschwend A, Straumann A, Helbling A.   +5 more
europepmc   +1 more source

Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration (RISE‐AMD): Safety data

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan, Celine Lee, Kaweh Daniel Zohalinejad, Mads Odgaard Mæng, Nanna Würtz Fabrin, Sigurrós Jónsdóttir, Anne Kjærsgaard Hassing, Søren Kveiborg Yde, Charles C. Wykoff, Henrik Vorum, Yousif Subhi, Marie Ørskov, Lasse Jørgensen Cehofski   +12 more
wiley   +1 more source

Real‐world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study

Acta Ophthalmologica, EarlyView.
Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider, Leyla Turan, Farah Arif, Jakob Bjerager, Oliver Niels Klefter, Carsten Faber, Yousif Subhi, Javad Nouri Hajari   +7 more
wiley   +1 more source

The TOP‐GERD Trial: Comparative Efficacy of Tegoprazan Versus Pantoprazole in the Treatment of Erosive Oesophagitis in a Non‐Asian Population

Alimentary Pharmacology &Therapeutics, EarlyView.
In this randomized, double‐blind trial in Mexican adults with erosive oesophagitis, tegoprazan did not significantly improve the primary 4‐week ITT healing endpoint versus pantoprazole (88.9% vs. 79.4%; p = 0.33), but produced faster symptom improvement. Encouraging per‐protocol and severe‐oesophagitis findings warrant confirmation.
José M. Remes‐Troche, Luis Raúl Valdovinos‐García, C. Prakash Gyawali, José Luis Vargas‐Basurto, Carlos Alberto Reyes‐Medina, Gisselle Vanessa González‐Hernández, A. Rafael Bernal Mendez, H. H. Barragán Cordova, Pablo Thomas‐Dupont, Peter Grube‐Pagola   +9 more
wiley   +1 more source

Brain calcification‐associated JAM2 pathogenic mutations impair JAM2–JAM3 tight junction structure and the blood–brain barrier integrity

Brain Pathology, EarlyView.
Pathogenic JAM2 mutations disrupt the JAM2–JAM3 heterodimer structure and tight junction integrity, leading to blood–brain barrier breakdown. Consequently, Jam2‐deficient mice develop prominent midbrain calcification and significant motor impairments, identifying the JAM2–JAM3 interaction as a vital target for primary brain calcification therapeutics ...
Dehao Yang, Lebo Wang, Chenxin Ying, Yihua Shi, Yuru Guo, Haotian Wang, Xinhui Chen, Yaoting Wang, Xinchen Wang, Fan Zhang, Xiaosheng Zheng, Yiling Chen, Haoyu Wang, Zhiru Lin, Jiaxiang Li, Haibin Xia, Jiawen Chen, Feng Fu, Bo Wang, Sheng Wu, Ping Wang, Fei Xie, Zhidong Cen, Zhiping Wang, Wei Luo   +24 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source